drugset / Trial / NCT07331272

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

NCT07331272 ↗

Phase 1 Recruiting 38 enrolled Nanjing Legend Biotech Co.
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.

Timeline

Start
2026-01-29
Primary completion
2028-01-31
Completion
2030-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject LUCAR-G79D Cell therapy — Other